Comparative Pharmacology
Head-to-head clinical analysis: BENZONATATE versus PROVAL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZONATATE versus PROVAL 3.
BENZONATATE vs PROVAL #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
100 mg to 200 mg orally three times daily as needed for cough.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Category A/B
Category C
Antitussive
Antitussive